Let's talk about the Data and Safety Monitoring Committee of the TOGETHER trial.

And if committees sound boring, I promise this 🧵 will be anything but.

Every version of the TOGETHER trial protocol available contains this paragraph:
So who is in the DSMC for the TOGETHER trial? The ivm paper supplemental appendix gives us some names:
So, doing a basic check, Orbinski seems to have co-written 9 publications with Edward Mills, the mastermind behind the TOGETHER trial. That sounds significant, but perhaps it's OK.
Sonal Singh has a more substantial co-authorship connection with Mills, having written 29 papers together.
What about Thorlund? Wait, what?

... They've literally written over 100 papers together. They really seem to be tight.
The wayback machine gives us the clue we need. When the trial started, in the first version of the website, this FAQ refers to Mills and Thorlund as joint leads of the project. Not quite so independent then?
There's something else that's strange about the first version of that page though. It points all emails to a company I haven't heard before, called MTEK Sciences. I wonder who they are.
Searching for that name shows a lot of very interesting material. This page here has quite the trove, including 2 grants from the BMGF. devex.com/organizations/…

However it is this paragraph that is most familiar:
Looking into the concept of the Highly Efficient Clinical Trial, this paper shows up: researchgate.net/publication/33…
A few things of interest: MTEK employed both Thorlund and Mills. One more relevant name: Jonas Haggstrom. He is also part of the DSMC of TOGETHER.

Finally, both Mills and Haggstrom were also simultaneously affiliated with the BMGF, who funds the TOGETHER trial.
Trying to understand what happened to MTEK I hit the jackpot: Acquired by CYTEL in 2019, and Mills as well as Thorlund are referred to as "Founding Partners and Directors". It's basically their startup.

I can't help but wonder if MTEK stands for "Mills Thorlund Edward Kristian".
Given all that, I'm not sure how this DSMC can be considered independent. Thorlund seems just as invested in the success of the research protocol as Mills, and Haggstrom seems to also be very tightly linked (and still employed by CYTEL). Surely someone noticed?
Actually someone did. In the open peer review of the protocol, this very issue was raised by a pair of Danish reviewers:
Mills responded to their concerns thus:
The reviewers did not budge and did not give the protocol their full approval, since Mills refused to remove Thorlund as chair of the DSMC and only took his vote away.

Why would they insist on having Thorlund on an "independent" Data and Safety Monitoring Board?
The authors give their final response with two references. One is the trial design paper with Mills and Thorlund as co-authors, and the other is literally a book on Data Monitoring Committees in Clinical Trials. This might be Danish humor.
It is stunning that the authors not only appointed a clearly non-independent DSMC for their trial, they actually more or less ignored direct reviewer advice pointing this out. And yet they insist repeating on every version of the protocol that the DSMC will have no involvement...

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Alexandros Marinos

Alexandros Marinos Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @alexandrosM

Apr 7
TOGETHER Trial : The Ethics Violations. 🧵

The first violation is perhaps somewhat small. They were recruiting and treating before approval for the trial by the local ethics board. Approval was granted on Jan 18, but the Metformin arm was recruiting since Jan 15. ImageImage
Brazilian ethics approval here: togethertrial.com/s/PB_PARECER_C…

Metformin paper here: pubmed.ncbi.nlm.nih.gov/34927127/
However the bigger violation IMHO is the second one. It is clear that by Feb 15, or at most by the 19th, they had requested approval to move to a high-dose ivermectin trial, ending their ludicrous single dose trial. togethertrial.com/s/National-Eth… Image
Read 11 tweets
Apr 7
If what he says is true, his track record throughout the pandemic must have been spectacular, right? Given these claims, it's only fair we do a review of the amazing positions this man has held throughout the pandemic. Image
He came strong out of the gate in January 2020... Image
His February 2020 was something to remember... Image
Read 16 tweets
Apr 6
Data Sharing in the TOGETHER trial.

What they said in the pre-registration on clinicaltrials.gov
What they said on the fluvoxamine paper... (protocol termination turned into publication)
What Mills said to Kirsch (notice the shift in responsibilities for the decision)
Read 7 tweets
Apr 4
TOGETHER trial: The Magical 3-day Placebo Group 🧵

Why is the per-protocol placebo (blue) curve shifted left compared to ITT/mITT placebo groups? It appears the per-protocol analysis gives lower superiority probability not because ivm did worse, but because placebo did better.
This is most curious. How can one placebo group do better than others? One possibility is that it's just luck. Another might be that it's not properly randomized compared to the treatment group.

Say... when did the 3-day placebo group start?
Thankfully, high quality studies register their protocols online, so the investigators can't mess with their designs as the data comes in. TOGETHER has 4 versions. The March 21 one should've been the one active when IVM arm begun recruiting 2 days later. clinicaltrials.gov/ct2/history/NC…
Read 15 tweets
Apr 4
To @daveyalba: kindly consider correcting your recent article, given that Malone has a pretty legitimate claim to the title of inventor. See detailed analysis with specific evidence below. nytimes.com/2022/04/03/tec…
OK, fine, let's give this NYT piece on Malone a bit of a fact check shall we? 🧵

To start, this contravenes many of his statements that I've seen, and the fact that he is vaccinated, which he states in almost every interview.
These may not be the authorities you're looking for in matters of mrna technology?
Read 23 tweets
Apr 3
Why was the TOGETHER trial ivm arm terminated?

NEJM Paper says the futility thresholds were 20/40/60% posterior probability of efficacy.

Website says that the trial was stopped for futility.

Yet the published probabilities of efficacy are all >60%.

What am I missing?
Indeed, from an interview of the principal investigator, we have him saying clearly that that they intended to get 800 patients, and they stopped about 85% of the way. Given that the Gamma variant was lifting, this could have made a huge difference. halifaxexaminer.ca/featured/whats…
To demonstrate why this matters, the results released on August 11, 2021, calculated a probability of superiority at 76%. The results we saw published report it at 79.4%. This could mean nothing, but it might indicate that the last few patients admitted fared exceedingly well.
Read 10 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(